INNATE PHARMA (EPA:IPH) | WebDisclosure

Basculer en Français

10965	Companies
240137	Keywords
168910	Articles
129233	Press releases

Home
Companies
INNATE PHARMA

PRESS RELEASE

published on 01/16/2025 at 07:00, 1 year 7 months ago

Total du nombre de droits de vote et du capital / Information relative au nombre total de droits de vote et d'actions composant le capital
Innate Pharma publie le nouveau nombre d'actions et de droits de vote au 31 décembre 2024 conformément à la réglementation financière. Détails sur son capital social et ses projets d'immunothérapie contre le cancer

Droits De Vote Actions Immunothérapie Cancer Innate Pharma
PRESS RELEASE

published on 01/16/2025 at 07:00, 1 year 7 months ago

Total number of voting rights and capital / Information on the total number of voting rights and the number of shares making up the capital
Innate Pharma releases shares and voting rights update as of December 31, 2024, in compliance with regulations. Learn more about the global biotech company's innovative immunotherapies for cancer patients

Voting Rights Shares Biotechnology Immunotherapy Innate Pharma
BRIEF

published on 12/20/2024 at 07:05, 1 year 8 months ago

Innate Pharma à la 43ème J.P. Morgan Healthcare Conference

Investisseurs Présentation En Direct Immunothérapie Innate Pharma J.P. Morgan Conference
BRIEF

published on 12/20/2024 at 07:05, 1 year 8 months ago

Innate Pharma at the 43rd JP Morgan Healthcare Conference

Investors Immunotherapy Innate Pharma JP Morgan Conference Live Presentation
PRESS RELEASE

published on 12/20/2024 at 07:00, 1 year 8 months ago

Informations privilégiées / Autres communiqués
Innate Pharma annonce sa participation à la 43ème J.P. Morgan Healthcare Conference avec présentations de ses dirigeants. Focus sur les traitements d'immunothérapies contre le cancer

Cancer Innate Pharma Biotechnologies Immunothérapies J.P. Morgan Healthcare Conference
PRESS RELEASE

published on 12/20/2024 at 07:00, 1 year 8 months ago

Inside Information / Other news releases
Innate Pharma to participate in the 43rd Annual J.P. Morgan Healthcare Conference with CEO Jonathan Dickinson and other executives presenting. Company focuses on developing immunotherapies for cancer patients

Biotechnology Innate Pharma Immunothérapies Cancer Patients J.P. Morgan Healthcare Conference
BRIEF

published on 12/06/2024 at 07:05, 1 year 9 months ago

Innate Pharma : Investissement de 7,9 millions de dollars pour IPH6501

Investissement Essai Clinique Innate Pharma Lymphome Folliculaire IPH6501
BRIEF

published on 12/06/2024 at 07:05, 1 year 9 months ago

Innate Pharma: Investment of 7.9 million dollars for IPH6501

Investment Clinical Trial Innate Pharma IPH6501 Follicular Lymphoma
PRESS RELEASE

published on 12/06/2024 at 07:00, 1 year 9 months ago

Informations privilégiées / Autres communiqués
Innate Pharma et l'Institut d'Innovation pour le Lymphome Folliculaire (IFLI) signent un accord d'investissement jusqu'à 7,9 millions de dollars pour le développement d'IPH6501 dans le lymphome folliculaire

Investissement Innate Pharma Lymphome Folliculaire IPH6501 IFLI
BRIEF

published on 11/20/2024 at 07:05, 1 year 9 months ago

Innate Pharma dévoile son calendrier financier pour 2025

Résultats Annuels Innate Pharma Calendrier Financier 2025 Assemblées Et Publications Cotisation Euronext Et Nasdaq

Accesswire

Published on 09/12/2026 at 02:35, 11 hours 49 minutes ago

Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 15 hours 24 minutes ago

Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 16 hours 19 minutes ago

Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 59 minutes ago

Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 21 hours 24 minutes ago

Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors

View all ACCESSWIRE

EQS Group

Published on 09/12/2026 at 07:30, 6 hours 54 minutes ago

NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 16 hours 9 minutes ago

Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 16 hours 14 minutes ago

Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 40 minutes ago

DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 20 hours 9 minutes ago

CGTN: How BRICS creates new opportunities for Global South development

Les Echos

Published on 09/11/2026 at 07:00, 1 day 7 hours ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 1 day 7 hours ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 1 day 7 hours ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 7 hours ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE